Freedom From Long-term Polymer Exposure

Professors Ian Meredith, Adrian Banning and Tan Huay Cheem provide their commentary about the SYNERGY stent platform, and the recently reported data from the EVOLVE Trial 4-Year and EVOLVE II Trial Diabetes Substudy 12 month presentations.  In addition, they also provide their analysis of the increasing evidence of how the SYNERGY stent may lead to optimal healing and reducing the risk of neoathersclerosis.